Trazimera (trastuzumab-qyyp) Injection, 150 mg Single-Dose Vial, Powder for Reconstitution, 15 mL
Trazimera is a biosimilar to Herceptin (trastuzumab) containing 150 mg of trastuzumab-qyyp as a lyophilized powder for reconstitution in a single-dose vial. It is indicated for the treatment of HER2-overexpressing breast cancer and metastatic gastric cancer. Each 15 mL vial provides a sterile, preservative-free preparation for intravenous infusion after reconstitution.
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Vendor Pricing Comparison
Sorted by lowest price · Add now, sign in at checkout
Trazimera is a biosimilar to Herceptin (trastuzumab) containing 150 mg of trastuzumab-qyyp as a lyophilized powder for reconstitution in a single-dose vial. It is indicated for the treatment of HER2-overexpressing breast cancer and metastatic gastric cancer. Each 15 mL vial provides a sterile, preservative-free preparation for intravenous infusion after reconstitution.
1 vendor
